Pratik Shah

Dr. Pratik Shah


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2026 in International Journal of Cancer Care and Delivery
Verified
Journal Article
Open access
PDF file
ASAdit Singhal
Adit Singhal
CCCho Han Chiang
Cho Han Chiang
PSPratik Shah
Pratik Shah
From the 2026 National Summit on Hematologic Cancers

Verified
Journal Article
Open access
PDF file
PSPratik Shah
Pratik Shah
ANAnita Ng
Anita Ng
ASAndrew J Shih
Andrew J Shih
TPTony Pham
Tony Pham
JWJustin Wang
Justin Wang
DGDouglas GLADSTONE
Douglas GLADSTONE
Classic Hairy Cell Leukemia (cHCL) and related conditions are rare, indolent B-cell malignancies characterized by distinctive morphological, immunophenotypic, and molecular features. Over the past decade, major advances in understanding the pathophysiology and molecular underpinnings have reshaped diagnostic and therapeutic approaches. This review synthesizes current knowledge on the cellular origins and signaling pathways that drive cHCL and Hairy Cell Variant (HCL-v)/splenic B-cell lymphoma/leukemia (SBLPN) and other molecular aberrations in disease pathogenesis. We discuss evolving diagnostic modalities, including flow cytometry, immunohistochemistry, and next-generation sequencing, that enhance diagnostic precision and disease monitoring. Additionally, we examine established and emerging therapeutic strategies—from purine nucleoside analogs (PNA) to targeted inhibitors and immunotherapies—that have significantly improved patient outcomes while highlighting challenges such as relapse and treatment resistance. By integrating insights from molecular biology and clinical practice, this review aims to provide a comprehensive understanding of cHCL and related disorders.

6 August 2025 in Lymphatics
Verified
Journal Article
Open access
PDF file
ASAdit Singhal
Adit Singhal
DMDavid Mueller
David Mueller
BABenjamin Ascherman
Benjamin Ascherman
PSPratik Shah
Pratik Shah
WAWint Yan Aung
Wint Yan Aung
MNMaria J Nieto
Maria J Nieto
Hodgkin’s Lymphoma (HL) affects approximately 8500 individuals annually in the United States. The 5-year relative survival rate has improved to 88.5%, driven by transformative advances in immunotherapy and precision oncology. The integration of Brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) has redefined treatment paradigms. The phase III SWOG S1826 trial established nivolumab plus doxorubicin, vinblastine, and dacarbazine (N + AVD) as an emerging new standard for advanced-stage HL, achieving a 2-year progression-free survival (PFS) of 92% compared to 83% for BV plus AVD (HR 0.48, 95% CI: 0.33–0.70), with superior safety, particularly in patients over 60. In relapsed/refractory HL, pembrolizumab outperforms BV, with a median PFS of 13.2 versus 8.3 months (HR 0.65, 95% CI: 0.48–0.88), as demonstrated in the KEYNOTE-204 trial. Emerging strategies, including novel ICI combinations, minimal residual disease (MRD) monitoring via circulating tumor DNA (ctDNA), and artificial intelligence (AI)-driven diagnostics, promise to further personalize therapy. This review synthesizes HL’s epidemiology, pathogenesis, diagnostic innovations, and therapeutic advances, highlighting the role of precision medicine in addressing unmet needs and disparities in HL care.

30 July 2026 in Lymphatics
Verified
Journal Article
Open access
PDF file
MWMonica Wallin
Monica Wallin
TRTeshmanie Rampersaud
Teshmanie Rampersaud
SKSally Ko
Sally Ko
RARizwan Atiq
Rizwan Atiq
BBBoisclair Boisclair
Boisclair Boisclair
PSPratik Shah
Pratik Shah
Venetoclax-based therapy is effective in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but tumor lysis syndrome (TLS) risk necessitates a resource-intensive five-week dose ramp-up with intravenous hydration, frequent laboratory monitoring, and clinic-based observation, creating logistical barriers particularly in community settings. We conducted a single-center, IRB-approved retrospective pilot study of 30 patients with CLL/SLL who underwent a cytoreduction-adapted, IV-free outpatient venetoclax ramp-up with reduced laboratory monitoring between 2023 and 2026. All patients received cytoreductive therapy—predominantly single-agent BTKi—and met protocol-defined low-tumor-burden criteria (ALC < 20 × 109/L, lymph nodes < 5 cm, no splenomegaly, CrCl > 45 mL/min) before venetoclax initiation. Venetoclax was self-administered at home with laboratory monitoring reduced to a single approximately 12-h post-dose assessment per dose-escalation week. Median age was 71 years; 80% had received ≥2 prior therapy lines, and 37% had high-risk cytogenetics. Monitoring compliance was 100%. No laboratory or clinical TLS, IV hydration, hospitalizations, dose interruptions, treatment discontinuations, or deaths occurred during ramp-up. These pilot data support the feasibility and early safety of simplified outpatient venetoclax initiation in adequately cytoreduced patients and warrant prospective multicenter validation.

25 September 2026 in International Journal of Cancer Care and Delivery
Verified
Journal Article
Open access
PDF file
CCCho Han Chiang
Cho Han Chiang
ASAdit Singhal
Adit Singhal
PSPratik Shah
Pratik Shah
From the 2026 National Summit on Hematologic Cancers

25 September 2026 in International Journal of Cancer Care and Delivery
Verified
Journal Article
Open access
PDF file
MWMonica Wallin
Monica Wallin
TRTeshmanie Rampersaud
Teshmanie Rampersaud
SKSally Ko
Sally Ko
BBBoisclair Boisclair
Boisclair Boisclair
ASAdit Singhal
Adit Singhal
PSPratik Shah
Pratik Shah
From the 2026 National Summit on Hematologic Cancers